SG11201901137UA - Silk-derived protein for treating inflammation - Google Patents

Silk-derived protein for treating inflammation

Info

Publication number
SG11201901137UA
SG11201901137UA SG11201901137UA SG11201901137UA SG11201901137UA SG 11201901137U A SG11201901137U A SG 11201901137UA SG 11201901137U A SG11201901137U A SG 11201901137UA SG 11201901137U A SG11201901137U A SG 11201901137UA SG 11201901137U A SG11201901137U A SG 11201901137UA
Authority
SG
Singapore
Prior art keywords
international
silk
sdp
minnesota
rule
Prior art date
Application number
SG11201901137UA
Other languages
English (en)
Inventor
Brian D Lawrence
David W Infanger
Original Assignee
Silk Technologies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Silk Technologies Ltd filed Critical Silk Technologies Ltd
Publication of SG11201901137UA publication Critical patent/SG11201901137UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C07K14/43586—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from silkworms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/14—Eye parts, e.g. lenses, corneal implants; Implanting instruments specially adapted therefor; Artificial eyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Insects & Arthropods (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
SG11201901137UA 2016-08-12 2017-08-12 Silk-derived protein for treating inflammation SG11201901137UA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662374532P 2016-08-12 2016-08-12
US201662407863P 2016-10-13 2016-10-13
US201762467697P 2017-03-06 2017-03-06
PCT/US2017/046659 WO2018031973A1 (en) 2016-08-12 2017-08-12 Silk-derived protein for treating inflammation

Publications (1)

Publication Number Publication Date
SG11201901137UA true SG11201901137UA (en) 2019-03-28

Family

ID=61163249

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201901137UA SG11201901137UA (en) 2016-08-12 2017-08-12 Silk-derived protein for treating inflammation

Country Status (10)

Country Link
US (2) US11242367B2 (de)
EP (1) EP3496662A4 (de)
JP (1) JP2019531334A (de)
KR (1) KR102275012B1 (de)
CN (1) CN109862851A (de)
AU (1) AU2017310520A1 (de)
CA (1) CA3033507A1 (de)
MX (1) MX2019001633A (de)
SG (1) SG11201901137UA (de)
WO (1) WO2018031973A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3182985B1 (de) * 2014-08-20 2020-01-08 Silk Technologies Ltd. Aus fibroin gewonnene proteinzusammensetzung
US20210236644A1 (en) 2017-11-10 2021-08-05 Cocoon Biotech Inc. Ocular applications of silk-based products
AU2020288624A1 (en) 2019-06-04 2022-02-03 Cocoon Biotech Inc. Silk-based products, formulations, and methods of use
KR102374291B1 (ko) * 2019-09-10 2022-03-14 강릉원주대학교산학협력단 천연 포졸란을 포함하는 사료 첨가제 조성물
CN114980839A (zh) * 2019-11-15 2022-08-30 蚕丝科技有限公司 丝蛋白的稳定制剂
IT201900023142A1 (it) * 2019-12-05 2021-06-05 Sifi Spa Composizione topica oculare contenente metaboliti della fermentazione di lactobacillus
KR102194995B1 (ko) * 2020-09-16 2020-12-28 장혜란 진단을 위한 개선된 건조체액의 안정화 조성물 및 이의 응용방법
CN114685825B (zh) * 2022-03-22 2023-02-28 浙江大学 一种蚕丝蛋白共晶凝胶的制备方法及其产品和应用

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5931520B2 (ja) 1979-03-22 1984-08-02 カネボウ株式会社 絹フイブロインペプチド水溶液の製造法
IL101850A (en) 1991-06-13 1996-01-31 Janssen Pharmaceutica Nv History 11-) 4-Pipridinyl (-Imidazo] B-1, 2 [] 3 [Benzazepine, their preparation and pharmaceutical preparations containing them
CA2125060C (en) 1993-07-02 1999-03-30 Henry P. Dabrowski Ophthalmic solution for artificial tears
JPH0767686A (ja) 1993-09-06 1995-03-14 Shinano Kenshi Co Ltd 低分子量の絹フィブロインペプチドの製造方法
US5760004A (en) * 1994-11-21 1998-06-02 Protein Polymer Technologies, Inc. Chemical modification of repetitive polymers to enhance water solubility
JP3449658B2 (ja) 1994-12-21 2003-09-22 杏林製薬株式会社 安定性に優れた８−アルコキシキノロンカルボン酸水和物並びにその製造方法
US5895645A (en) 1995-01-31 1999-04-20 Bausch & Lomb Incorporated Opthalmic solution for artificial tears
JPH08295697A (ja) 1995-04-26 1996-11-12 Kanebo Ltd 高濃度絹フィブロイン水溶液の製造方法
AU2022599A (en) 1997-12-31 1999-07-19 Kimberly-Clark Worldwide, Inc. Method of reducing molecular weights and polydispersity indices of polymers of ethylene oxide
FR2774588B1 (fr) 1998-02-11 2000-05-05 Oreal Composition cosmetique ou dermatologique contenant au moins une proteine de soie d'arachnides naturelle, recombinante ou un analogue
DE69932313T2 (de) 1998-08-21 2007-07-19 Senju Pharmaceutical Co., Ltd. Wässerige flüssige zubereitungen
JP2000143472A (ja) 1998-11-10 2000-05-23 Hiroshi Akai 紫外線吸収機能を有する化粧剤
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
HUP0303197A3 (en) 2000-07-14 2008-03-28 Allergan Inc Compositions containing alpha-2 adrenergic agonist components
US8858961B2 (en) 2000-07-14 2014-10-14 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
RU2291685C2 (ru) 2000-07-14 2007-01-20 Аллерган Инк. Композиции, содержащие терапевтически активные компоненты, обладающие повышенной растворимостью
US20030206897A1 (en) 2000-09-13 2003-11-06 The Procter & Gamble Company Cosmetic compositions
IT1316885B1 (it) 2000-10-02 2003-05-13 Consorzio Per Gli Studi Uni Procedimento per la preparazione di un tessuto non tessuto in fibroinadi seta.
JP4669662B2 (ja) 2001-10-25 2011-04-13 ユニヴァーシティー オブ コネティカット 生物活性材料、生物活性材料の製法およびその使用方法
EP1459728A4 (de) 2001-11-29 2005-04-20 Nat Inst Of Agrobio Sciences Emulgator und verfahren zu seiner herstellung
US7351404B2 (en) 2002-02-04 2008-04-01 Allergan, Inc. Method of enhancing hair growth
US7642258B2 (en) 2002-04-19 2010-01-05 Allergan, Inc. Combination of brimonidine and timolol for topical ophthalmic use
US7030149B2 (en) 2002-04-19 2006-04-18 Allergan, Inc. Combination of brimonidine timolol for topical ophthalmic use
WO2004062697A2 (en) 2003-01-07 2004-07-29 Tufts University Silk fibroin materials and use thereof
US7060260B2 (en) 2003-02-20 2006-06-13 E.I. Du Pont De Nemours And Company Water-soluble silk proteins in compositions for skin care, hair care or hair coloring
US7193038B2 (en) 2003-02-28 2007-03-20 National Institute Of Agrobiological Sciences Extraction and utilization of cell growth-promoting peptides from silk protein
US7115388B2 (en) 2003-03-14 2006-10-03 National Institute Of Agrobiological Sciences Production of functional polypeptides originating from silk protein and use thereof
US20050196370A1 (en) 2003-03-18 2005-09-08 Zhi-Jian Yu Stable ophthalmic oil-in-water emulsions with sodium hyaluronate for alleviating dry eye
CA2562415C (en) 2003-04-10 2015-10-27 Tufts University Concentrated aqueous silk fibroin solutions free of organic solvents and uses thereof
CA2468664C (en) 2003-06-03 2012-03-06 Allergan, Inc. Ketorolac tromethamine compositions for treating or preventing ocular pain
AU2004263149B2 (en) 2003-08-07 2010-08-19 Allergan, Inc. Compositions for delivery of therapeutics into the eyes and methods for making and using same
US20050059583A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
EP1682537B1 (de) 2003-11-05 2012-03-28 SARcode Bioscience Inc. Modulatoren der zellulären adhäsion
US20050202097A1 (en) 2004-03-12 2005-09-15 Melbj Holdings, Llc, Florida Lubricant for the ocular surface
EP1609801A1 (de) 2004-06-25 2005-12-28 Technische Universität München Proteine von natürlicher Herkunft und daraus hergestellte Materialen
EP1773864A4 (de) 2004-07-31 2009-02-18 Biogrand Co Ltd Seidenpeptid, das neuroprotektive und neurofunktionelle wirkungen verbessert, und verfahren zu dessen herstellung
US8569367B2 (en) 2004-11-16 2013-10-29 Allergan, Inc. Ophthalmic compositions and methods for treating eyes
WO2010102078A1 (en) 2009-03-04 2010-09-10 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
US7851504B2 (en) 2005-03-16 2010-12-14 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
SI1881823T1 (sl) 2005-05-17 2015-04-30 Sarcode Bioscience Inc. Sestavki in postopki za zdravljenje bolezni oäśesa
ES2403733T3 (es) 2005-10-05 2013-05-21 Commonwealth Scientific And Industrial Research Organisation Proteínas de seda
ES2594655T3 (es) 2006-03-31 2016-12-21 Vistakon Pharmaceuticals, Llc Tratamiento de alergias oculares
WO2007130364A2 (en) 2006-05-01 2007-11-15 Riolan Technologies, Inc. Compositions, methods, and kits for treating dry eye
US20080219938A1 (en) 2007-03-07 2008-09-11 Grune Guerry L SPF compositions
KR20100029217A (ko) 2007-05-29 2010-03-16 트러스티즈 오브 터프츠 칼리지 음파 처리를 이용한 실크 피브로인 겔화 방법
CN101194666A (zh) 2007-11-28 2008-06-11 吴江市方霞企业信息咨询有限公司 蚕蛹丝素蛋白功能性食品
WO2009088119A1 (en) 2008-01-07 2009-07-16 Bioleaders Corporation Composition for preventing or treating dry eye syndrome comprising poly-gamma-glutamic acid
US7842714B2 (en) 2008-03-03 2010-11-30 Allergan, Inc. Ketorolac tromethamine compositions for treating ocular pain
US8080562B2 (en) 2008-04-15 2011-12-20 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
US8569730B2 (en) 2008-07-08 2013-10-29 Sandisk 3D Llc Carbon-based interface layer for a memory device and methods of forming the same
JP5909362B2 (ja) 2009-03-04 2016-04-26 タフツ ユニバーシティー／トラスティーズ オブ タフツ カレッジ 抗生物質送達のための絹フィブロインシステム
WO2010123947A2 (en) 2009-04-20 2010-10-28 Allergan, Inc. Silk fibroin hydrogels and uses thereof
MX2011013007A (es) 2009-06-05 2012-02-28 Allergan Inc Lagrimas artificiales y usos terapeuticos.
CA2812635A1 (en) 2009-07-14 2011-01-20 Trustees Of Tufts College Electrospun silk material systems for wound healing
WO2011050175A1 (en) 2009-10-21 2011-04-28 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
US9603971B2 (en) 2010-03-05 2017-03-28 Trustees Of Tufts College Silk-based ionomeric compositions
US8309689B2 (en) 2010-05-20 2012-11-13 Taipei Medical University High yield dialysis-free process for producing organosoluble regenerated silk fibroin
WO2011160098A2 (en) 2010-06-17 2011-12-22 Tufts University Silk optical particles and uses thereof
US20140193466A1 (en) 2011-06-07 2014-07-10 Cornell University Silk compositions and methods of using same
CN102860969A (zh) 2011-07-07 2013-01-09 刘畅 一种大豆眼霜
US20150037422A1 (en) 2012-02-22 2015-02-05 Trustees Of Tufts College Compositions and methods for ocular delivery of a therapeutic agent
US9056063B2 (en) 2012-03-13 2015-06-16 James E. Hanson Natural sunscreen composition
WO2013159101A1 (en) 2012-04-20 2013-10-24 Trustees Of Tufts College Silk fibroin-based personal care compositions
CN104797574B (zh) 2012-07-25 2019-11-22 原生质生物科学股份有限公司 Lfa-1抑制剂及其多晶型物
WO2014127007A1 (en) 2013-02-12 2014-08-21 Seryx Biomedical, Inc. Ophthalmic formulation derived from silk protein
MX367597B (es) 2013-03-15 2019-08-28 Patheon Softgels Inc Cápsulas a base de seda.
KR20210149207A (ko) 2013-03-15 2021-12-08 트러스티즈 오브 터프츠 칼리지 저분자량 실크 조성물 및 안정화 실크 조성물
CN103239707A (zh) 2013-05-22 2013-08-14 江苏紫石化工科技有限公司 治疗近视的滴眼液
KR102379848B1 (ko) 2013-09-30 2022-03-28 실크 테라퓨틱스, 인코퍼레이티드 실크 단백질 단편 조성물 및 이로부터 제작된 물품
AU2014353110B2 (en) 2013-11-19 2018-05-10 Cornell University Tissue scaffold materials for tissue regeneration and methods of making
EP3182985B1 (de) * 2014-08-20 2020-01-08 Silk Technologies Ltd. Aus fibroin gewonnene proteinzusammensetzung
US10758645B2 (en) * 2014-12-17 2020-09-01 Tufts University Injectable, flexible hydroxyapatite-silk foams for osteochondral and dental repair
US10953132B2 (en) * 2016-04-08 2021-03-23 Cornell University Method to enhance wound healing using silk-derived protein

Also Published As

Publication number Publication date
KR102275012B1 (ko) 2021-07-07
US11242367B2 (en) 2022-02-08
US20190169243A1 (en) 2019-06-06
CN109862851A (zh) 2019-06-07
MX2019001633A (es) 2019-09-18
KR20190042608A (ko) 2019-04-24
WO2018031973A1 (en) 2018-02-15
US20220332773A1 (en) 2022-10-20
EP3496662A1 (de) 2019-06-19
AU2017310520A1 (en) 2019-03-21
EP3496662A4 (de) 2019-10-30
JP2019531334A (ja) 2019-10-31
CA3033507A1 (en) 2018-02-15

Similar Documents

Publication Publication Date Title
SG11201901137UA (en) Silk-derived protein for treating inflammation
SG11201906297QA (en) Nucleic acids encoding crispr-associated proteins and uses thereof
SG11201908790PA (en) Glucocorticoid receptor modulators to treat cervical cancer
SG11201907034PA (en) Methods of treating influenza
SG11201909383PA (en) Customizable composite dressings for improved granulation and reduced maceration negative-pressure treatment
SG11201906431UA (en) Method for the treatment of thromboembolism
SG11201900809TA (en) Combination steerable catheter and systems
SG11201811019TA (en) Device for cardiac valve repair and method of implanting the same
SG11201806322QA (en) Maytansinoid derivatives, conjugates thereof, and methods of use
SG11201807784SA (en) 3-desoxy derivative and pharmaceutical compositions thereof
SG11201909960UA (en) Methods for improving memory and cognition and for treating memory and cognitive disorders
SG11201804814YA (en) Materials and methods for delivering nucleic acids to cochlear and vestibular cells
SG11201805828YA (en) Method of treating c3 glomerulopathy
SG11201908326YA (en) Methods of treating neurodegenerative diseases
SG11201909155VA (en) Ask1 inhibitor compounds and uses thereof
SG11201408153YA (en) Prostate-specific membrane antigen antibody drug conjugates
SG11201808804TA (en) A method to enhance wound healing using silk-derived protein
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201809908TA (en) Stabilized glycopeptide antibiotic formulations
SG11201809605PA (en) Compositions for and method of treating acid-base disorders
SG11201810525XA (en) Anti-gitr antibodies and uses thereof
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases
SG11201803834UA (en) Methods for treating conditions associated with masp-2 dependent complement activation
SG11201408240TA (en) Treatment of motor and movement disorder side effects associated with parkinson's disease treatments
SG11201903312VA (en) Sulfoxyalkyl organonitro and related compounds and pharmaceutical compositions for use in medicine